Patents Assigned to Quest Diagnostics
  • Publication number: 20200123596
    Abstract: Disclosed herein are methods and compositions for detecting Bordetella pertussis and Bordetella parapertussis by detecting the presence of the IS481 and IS1001 genomic insertion sequences, respectively.
    Type: Application
    Filed: October 29, 2019
    Publication date: April 23, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Michelle M. Tabb, Ming-Chou Lee, Lilly I. Kong, Ning Lu, Michael Aye, Fan Chen, Jules Chen
  • Publication number: 20200115759
    Abstract: Provided herein are methods for the diagnosis, or management of liver diseases, e.g., hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids.
    Type: Application
    Filed: September 20, 2019
    Publication date: April 16, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Kevin Qu, Ke Zhang, Maher Albitar
  • Publication number: 20200115760
    Abstract: Provided herein are methods for detecting and discriminating BRAF V600 mutations. Also provided herein are methods for diagnosis, prognosis, management, and treatment decisions of BRAF V600 mutation-related diseases or conditions.
    Type: Application
    Filed: September 20, 2019
    Publication date: April 16, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Amber C. Donahue, Yen-lin Peng
  • Patent number: 10620210
    Abstract: The present invention provides aptamers that specifically bind to the EGF receptor in a sample, and diagnostic and analytical methods using those aptamers. In some embodiments, the aptamers include a 3? cap. In some embodiments, the 3? cap is an inverted deoxythymidine. In some embodiments the aptamers include a spacer and at least one moiety selected from the group consisting of binding pair member and a detectable label, wherein the spacer is attached to the 5?-end of the aptamer and the moiety is attached the 5? end of the spacer. In some embodiments the spacer is hexaethylene glycol. In some embodiments, the binding pair member biotin. In some embodiments the detectable label is a fluorophore.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: April 14, 2020
    Assignees: Quest Diagnostics Investments Incorporated, Somalogic, Inc.
    Inventors: Chris Bock, Deborah Ayers, Malti P. Nikrad, Bharat Nathu Gawande, Jennifer C. Bertino, Weimin Sun, Charles M. Strom, Noh Jin Park
  • Patent number: 10619220
    Abstract: Provided herein are methods for identifying the presence or absence of a target nucleic acid from a microorganism using direct amplification without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids.
    Type: Grant
    Filed: October 7, 2016
    Date of Patent: April 14, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Maurice Exner, Luca Jacky, Yin-Peng Chen, Huong Mai, Michelle M. Tabb, Michael Aye
  • Patent number: 10598676
    Abstract: Methods are described for determining the amount of metabolites of leflunomide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying teriflunomide in a sample.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: March 24, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Karin O. Thomassian
  • Patent number: 10571455
    Abstract: Methods are described for measuring the amount of a vitamin B2 in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying vitamin B2 in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric techniques.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: February 25, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Changming Yang, Sum Chan
  • Publication number: 20200056240
    Abstract: The present disclosure provides methods for determining whether a patient exhibiting cystic fibrosis symptoms, or a patient at risk for cystic fibrosis, will benefit from treatment with one or more anti-cystic fibrosis therapeutic agents. These methods are based on detecting hereditary cystic fibrosis related mutations in small-volume dried biological fluid samples that are collected using a volumetric absorptive microsampling device. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: November 13, 2017
    Publication date: February 20, 2020
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Heather Sanders, Nigel J. Clarke
  • Patent number: 10534008
    Abstract: The invention relates to the detection of DHA and EPA. In a particular aspect, the invention relates to methods for detecting DHA and EPA by mass spectrometry and kits for carrying out such methods.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: January 14, 2020
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Scott M. Goldman, Julie A. Neidich
  • Patent number: 10528231
    Abstract: Computer systems and methods may display multi-dimensional data sets in a dynamically-generated ocular view, which may show the relationship between data points in the different dimensions. For example, such a data set may include in one dimension results of one or more laboratory tests and, in another dimension, body systems or functions that the respective tests may relate to. The ocular view may depict the relationships between the tests and the systems. By being generated dynamically, moreover, the ocular view may be able to present this information for arbitrary sets of test results, without a template having been generated in advance to specify the layout of some particular combination of results.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: January 7, 2020
    Assignee: Quest Diagnostics Investments Inc.
    Inventors: Peter Wilkinson, Kerry O'Brien
  • Patent number: 10519509
    Abstract: Provided herein are methods and compositions for the detection of in-frame deletion germline mutations in the CALR gene. Also provided are methods for determining the prognosis of myeloproliferative diseases and the likelihood of developing somatic mutations in genes involved in the JAK-STAT pathway.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: December 31, 2019
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Yongbao Wang, Daniel Jones
  • Publication number: 20190382826
    Abstract: The present disclosure provides methods for determining whether a patient exhibiting pertussis-like symptoms will benefit from treatment, with therapeutic agents that inhibit Bordetella holmesii. These methods are based on detecting Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii in a biological sample by assaying for the presence of the IS481, IS 1001, and hIS1001 target repeat elements, respectively. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: March 23, 2017
    Publication date: December 19, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Jules Chen, Michelle Tabb
  • Patent number: 10509016
    Abstract: Provided are methods for determining the amount of lacosamide in a sample using mass spectrometry. The methods generally involve ionizing lacosamide in a sample and detecting and quantifying the amount of the ion to determine the amount of lacosamide in the sample.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: December 17, 2019
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Beatrisa Boyadzhyan, Karin Thomassian, Anita Dermartirosian, Lou Jambor
  • Publication number: 20190376138
    Abstract: Methods for determining the presence or absence of expansion of CGG repeat sequence in the FMR1 gene presence or absence of expansion of CCG repeat sequence in the FMR2 gene are provided. The methods are useful in identifying an individual with normal/intermediate, versus premutation or full mutation allele of FMR1 gene and FMR2 gene due to the expansion of CGG repeats and CCG repeats in the 5?-untranslated region respectively. The methods are also useful for screening newborns for fragile X syndrome or for screening women to determine heterozygosity status with full premutation of the CCG repeat tract. The methods are also useful in estimating the premutation and full mutation carrier frequency and estimating the prevalence of FXTAS AND FXPOI in a population. The methods are simple, rapid and require small amount of sample.
    Type: Application
    Filed: March 18, 2019
    Publication date: December 12, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Feras Hantash, Weimin Sun, David C. Tsao, Dana Marie Root, Charles M. Strom
  • Patent number: 10501809
    Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: December 10, 2019
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
  • Patent number: 10501799
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: December 10, 2019
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Weimin Sun, Matthew J. McGinniss, Donghui Huang, Arlene Buller, Raymond Fenwick, Mei Peng, Franklin Quan
  • Publication number: 20190365779
    Abstract: The present technology is related to methods for detecting genetic alterations underlying intracranial neoplasms such as pituitary adenomas, meningiomas, and craniopharyngiomas. The methods disclosed herein are useful in determining whether a patient harboring an intracranial tumor will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: August 17, 2017
    Publication date: December 5, 2019
    Applicant: Quest Diagnostics Investments LLC
    Inventors: Michael J. McPhaul, Heather R. Sanders
  • Patent number: 10494629
    Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: December 3, 2019
    Assignee: Quest Diagnostics Investments LLC
    Inventors: Heather Sanders, Hai-Rong Li
  • Patent number: 10487367
    Abstract: Described herein are methods and kits for detecting the presence or absence of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene. The average expression of the 5? portion of the target gene is compared with the average expression of the 3? portion of the target gene to determine an intragenic differential expression (IDE). The IDE can then be used to determine if a dysregulation or a particular disease (or susceptibility to a disease) is present or absent in a subject or sample.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: November 26, 2019
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Shih-Min Cheng
  • Patent number: 10473675
    Abstract: Described herein are methods for determining the overall survival of maintenance hemodialysis patients. The methods include measuring low density lipoprotein (LDL) particle size and subfraction concentrations as prognostic tools for early mortality risk detection. For example, the presence of increased very small LDL concentration or decreased LDL particle size in blood-serum serves as a useful means for prognostic risk assessment and monitoring.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: November 12, 2019
    Assignees: Quest Diagnostics Investments Incorporated, Los Angeles Biomedical Research Institute
    Inventors: Kamyar Kalantar-Zadeh, Michael P. Caulfield, Wael A. Salameh